vs
Side-by-side financial comparison of Hologic (HOLX) and KeyCorp (KEY). Click either name above to swap in a different company.
KeyCorp is the larger business by last-quarter revenue ($2.0B vs $1.0B, roughly 1.9× Hologic). KeyCorp runs the higher net margin — 25.4% vs 17.1%, a 8.3% gap on every dollar of revenue. On growth, KeyCorp posted the faster year-over-year revenue change (131.8% vs 2.5%). KeyCorp produced more free cash flow last quarter ($2.1B vs $215.2M). Over the past eight quarters, KeyCorp's revenue compounded faster (14.4% CAGR vs 1.5%).
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
Key is a Japanese visual novel studio known for making dramatic and plot-oriented titles. It was formed on July 21, 1998, as a brand under the publisher Visual Arts, and is located in Kita, Osaka.
HOLX vs KEY — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.0B | $2.0B |
| Net Profit | $179.1M | $510.0M |
| Gross Margin | 56.0% | — |
| Operating Margin | 22.6% | 32.3% |
| Net Margin | 17.1% | 25.4% |
| Revenue YoY | 2.5% | 131.8% |
| Net Profit YoY | -10.9% | 309.0% |
| EPS (diluted) | $0.79 | $0.43 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.0B | $2.0B | ||
| Q3 25 | $1.0B | $1.9B | ||
| Q2 25 | $1.0B | $1.8B | ||
| Q1 25 | $1.0B | $1.8B | ||
| Q4 24 | $1.0B | $865.0M | ||
| Q3 24 | $988.0M | $695.0M | ||
| Q2 24 | $1.0B | $1.5B | ||
| Q1 24 | $1.0B | $1.5B |
| Q4 25 | $179.1M | $510.0M | ||
| Q3 25 | $187.2M | $489.0M | ||
| Q2 25 | $194.9M | $425.0M | ||
| Q1 25 | $-17.4M | $405.0M | ||
| Q4 24 | $201.0M | $-244.0M | ||
| Q3 24 | $178.6M | $-410.0M | ||
| Q2 24 | $194.5M | $274.0M | ||
| Q1 24 | $169.9M | $219.0M |
| Q4 25 | 56.0% | — | ||
| Q3 25 | 55.6% | — | ||
| Q2 25 | 56.3% | — | ||
| Q1 25 | 37.5% | — | ||
| Q4 24 | 56.8% | — | ||
| Q3 24 | 56.4% | — | ||
| Q2 24 | 55.4% | — | ||
| Q1 24 | 53.3% | — |
| Q4 25 | 22.6% | 32.3% | ||
| Q3 25 | 22.6% | 31.8% | ||
| Q2 25 | 24.9% | 29.3% | ||
| Q1 25 | -0.7% | 29.0% | ||
| Q4 24 | 22.5% | -92.6% | ||
| Q3 24 | 23.3% | -72.8% | ||
| Q2 24 | 24.1% | 22.0% | ||
| Q1 24 | 20.7% | 18.1% |
| Q4 25 | 17.1% | 25.4% | ||
| Q3 25 | 17.8% | 25.8% | ||
| Q2 25 | 19.0% | 23.1% | ||
| Q1 25 | -1.7% | 22.8% | ||
| Q4 24 | 19.7% | -54.7% | ||
| Q3 24 | 18.1% | -59.0% | ||
| Q2 24 | 19.2% | 18.0% | ||
| Q1 24 | 16.7% | 14.3% |
| Q4 25 | $0.79 | $0.43 | ||
| Q3 25 | $0.84 | $0.41 | ||
| Q2 25 | $0.86 | $0.35 | ||
| Q1 25 | $-0.08 | $0.33 | ||
| Q4 24 | $0.87 | $-0.30 | ||
| Q3 24 | $0.75 | $-0.47 | ||
| Q2 24 | $0.82 | $0.25 | ||
| Q1 24 | $0.72 | $0.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.4B | $10.2B |
| Total DebtLower is stronger | $2.5B | $9.9B |
| Stockholders' EquityBook value | $5.2B | $20.4B |
| Total Assets | $9.2B | $184.4B |
| Debt / EquityLower = less leverage | 0.48× | 0.49× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.4B | $10.2B | ||
| Q3 25 | $2.2B | $13.3B | ||
| Q2 25 | $1.9B | $11.6B | ||
| Q1 25 | $1.6B | $15.3B | ||
| Q4 24 | $2.0B | $17.5B | ||
| Q3 24 | $2.3B | $22.8B | ||
| Q2 24 | $2.4B | $15.5B | ||
| Q1 24 | $2.2B | $13.2B |
| Q4 25 | $2.5B | $9.9B | ||
| Q3 25 | $2.5B | $10.9B | ||
| Q2 25 | $2.5B | $12.1B | ||
| Q1 25 | $2.5B | $12.4B | ||
| Q4 24 | $2.5B | $12.1B | ||
| Q3 24 | $2.5B | $15.7B | ||
| Q2 24 | $2.5B | $16.9B | ||
| Q1 24 | $2.6B | $20.8B |
| Q4 25 | $5.2B | $20.4B | ||
| Q3 25 | $5.0B | $20.1B | ||
| Q2 25 | $4.8B | $19.5B | ||
| Q1 25 | $4.6B | $19.0B | ||
| Q4 24 | $4.8B | $18.2B | ||
| Q3 24 | $5.1B | $16.9B | ||
| Q2 24 | $5.0B | $14.8B | ||
| Q1 24 | $4.8B | $14.5B |
| Q4 25 | $9.2B | $184.4B | ||
| Q3 25 | $9.0B | $187.4B | ||
| Q2 25 | $8.8B | $185.5B | ||
| Q1 25 | $8.5B | $188.7B | ||
| Q4 24 | $8.7B | $187.2B | ||
| Q3 24 | $9.2B | $189.8B | ||
| Q2 24 | $8.9B | $187.4B | ||
| Q1 24 | $8.7B | $187.5B |
| Q4 25 | 0.48× | 0.49× | ||
| Q3 25 | 0.50× | 0.54× | ||
| Q2 25 | 0.52× | 0.62× | ||
| Q1 25 | 0.55× | 0.65× | ||
| Q4 24 | 0.53× | 0.67× | ||
| Q3 24 | 0.49× | 0.93× | ||
| Q2 24 | 0.51× | 1.14× | ||
| Q1 24 | 0.53× | 1.43× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $229.9M | $2.2B |
| Free Cash FlowOCF − Capex | $215.2M | $2.1B |
| FCF MarginFCF / Revenue | 20.5% | 104.8% |
| Capex IntensityCapex / Revenue | 1.4% | 5.3% |
| Cash ConversionOCF / Net Profit | 1.28× | 4.33× |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | $3.5B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $229.9M | $2.2B | ||
| Q3 25 | $355.1M | $396.0M | ||
| Q2 25 | $343.3M | $1.2B | ||
| Q1 25 | $169.4M | $-140.0M | ||
| Q4 24 | $189.3M | $664.0M | ||
| Q3 24 | $367.0M | $-1.2B | ||
| Q2 24 | $405.8M | $-217.0M | ||
| Q1 24 | $292.4M | $359.0M |
| Q4 25 | $215.2M | $2.1B | ||
| Q3 25 | $341.4M | $367.0M | ||
| Q2 25 | $330.5M | $1.2B | ||
| Q1 25 | $153.9M | $-150.0M | ||
| Q4 24 | $172.5M | $599.0M | ||
| Q3 24 | $350.6M | $-1.2B | ||
| Q2 24 | $385.3M | $-230.0M | ||
| Q1 24 | $279.6M | $347.0M |
| Q4 25 | 20.5% | 104.8% | ||
| Q3 25 | 32.5% | 19.4% | ||
| Q2 25 | 32.3% | 65.8% | ||
| Q1 25 | 15.3% | -8.5% | ||
| Q4 24 | 16.9% | 69.2% | ||
| Q3 24 | 35.5% | -175.8% | ||
| Q2 24 | 38.1% | -15.1% | ||
| Q1 24 | 27.5% | 22.6% |
| Q4 25 | 1.4% | 5.3% | ||
| Q3 25 | 1.3% | 1.5% | ||
| Q2 25 | 1.3% | 1.3% | ||
| Q1 25 | 1.5% | 0.6% | ||
| Q4 24 | 1.6% | 7.5% | ||
| Q3 24 | 1.7% | 2.4% | ||
| Q2 24 | 2.0% | 0.9% | ||
| Q1 24 | 1.3% | 0.8% |
| Q4 25 | 1.28× | 4.33× | ||
| Q3 25 | 1.90× | 0.81× | ||
| Q2 25 | 1.76× | 2.90× | ||
| Q1 25 | — | -0.35× | ||
| Q4 24 | 0.94× | — | ||
| Q3 24 | 2.05× | — | ||
| Q2 24 | 2.09× | -0.79× | ||
| Q1 24 | 1.72× | 1.64× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
KEY
Segment breakdown not available.
